Rademikibart IV for Acute Asthma and COPD Exacerbation
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-85
SponsorConnect Biopharm LLC
About this trial
A Phase 2, open-label, single-arm trial to evaluate IV rademikibart as an add-on treatment for acute exacerbation in participants with asthma or COPD with type 2 inflammation
Eligibility criteria
Qualifiers
Asthma cohort
Body weight of ≥40 kg and BMI ≤45 kg/m2 at SV1a.
Physician-diagnosed asthma
Currently receiving treatment with low, medium, to high dose ICS in combination with at least 1 additional asthma controller medication.
Disqualifiers
Asthma cohort
Regular use of immunosuppressive medication.
Unstable ischemic heart disease, cardiomyopathy, heart failure, uncontrolled hypertension.
Current or former smoker, with a smoking history of ≥5 pack-years if <30 years old or ≥10 pack-years if ≥30 years old
Trial design
Treatments tested in this trial
- Rademikibart
Treatment groups
40 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov